168. Ehlers-Danlos syndrome Clinical trials / Disease details

Clinical trials : 13 / Drugs : 21 - (DrugBank : 11) / Drug target genes : 11 - Drug target pathways : 103

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05432466 (ClinicalTrials.gov)	November 7, 2022	21/6/2022	Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome	A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome	Vascular Ehlers-Danlos Syndrome	Drug: ACER-002 (celiprolol) 200 mg BID;Drug: Placebo BID	Acer Therapeutics Inc.	NULL	Recruiting	15 Years	64 Years	All	150	Phase 3	United States
2	NCT00190411 (ClinicalTrials.gov)	October 2003	13/9/2005	Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type	Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME	Drug: celiprolol;Drug: Control	Assistance Publique - Hôpitaux de Paris	Aventis Pharmaceuticals	Completed	15 Years	65 Years	Both	54	Phase 4	France